Search Results
May 18, 2026, 07:00 ET Triquetra Health Launches Instant Aminos--First Free-Form EAA Tablets Delivering All 9 Essential Amino Acids with Zero Bloating
9 essential amino acids in an optimized ratio at the clinically-studied free-form dose, with leucine-leading concentrations exceeding the recognized mTOR activation threshold."If you've ever felt uncomfortable after a protein shake — bloated, heavy, or just off — that discomfort comes from digestion,"
More news about: Triquetra Health LLC
Apr 15, 2026, 15:26 ET Seragon Publishes Data for Longevity Drug SRN-901 Showing Significant Lifespan and Healthspan Extension
a Cox proportional hazards analysis revealed that SRN-901 treatment was associated with a 46% reduction in the hazard of death. While the benchmark mTOR inhibitor rapamycin increased median lifespan in adult mice by 21%, other comparator compounds like nicotinamide mononucleotide (NMN) and nicotinamide
More news about: Seragon Biosciences
Apr 15, 2026, 08:00 ET Kazia Therapeutics Strengthens Scientific Leadership with Appointment of Dr. Sudha Rao as Chief Scientific Officer to Lead Next-Generation Oncology Platform
Company's pipeline and expanding its next-generation platform capabilities, including:Paxalisib, a brain-penetrant dual PI3K/mTOR inhibitor being developed across oncology indications, including advanced breast cancer;NDL2, a novel PD-L1 protein degrader platform designed
More news about: Kazia Therapeutics Limited
Apr 13, 2026, 17:05 ET Kazia Therapeutics Expands Oncology Platform with First-in-Class SETDB1 Inhibitor Drug Development Platform
drug development company, based in Sydney, Australia. Our lead program is paxalisib, an investigational brain penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of cancer. Licensed from Genentech in late 2016, paxalisib is or has been the subject of ten
More news about: Kazia Therapeutics Limited
Mar 25, 2026, 17:30 ET Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update
The paper emphasizes (Z)-endoxifen's direct estrogen-receptor (ER) modulation, allosteric inhibition of PKC (notably PKC-β1), and effects along AKT/mTOR and NF-κB axes, mechanisms that together may help slow disease progression when used as an adjunct to standard care. Notably, the authors underscore
More news about: Atossa Therapeutics Inc
Jan 30, 2026, 08:00 ET Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2)
drug development company, based in Sydney, Australia. Our lead program is paxalisib, an investigational brain penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of cancer. Licensed from Genentech in late 2016, paxalisib is or has been the subject of ten
More news about: Kazia Therapeutics Limited
Jan 27, 2026, 08:00 ET Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer
populations, including earlier-stage TNBC and hormone receptor–positive, HER2-negative (HR+ / HER2-) breast cancer, where dysregulation of the PI3K/mTOR pathway is well established. Paxalisib's oral, once-daily administration offers a potentially convenient treatment option with minimal incremental burden
More news about: Kazia Therapeutics Limited
Jan 15, 2026, 09:00 ET Placental Scientist Wins March of Dimes Agnes Higgins Award
remaining in homeostasis depending on maternal conditions.Dr. Jansson showed that placental mTOR activation leads to fetal overgrowth, mTOR inhibition results in fetal growth restriction, and mTOR homeostasis is linked to optimal birth weight. These findings are critically important, as both fetal
More news about: March of Dimes
Jan 15, 2026, 09:00 ET La científica placentaria gana el premio Agnes Higgins de March of Dimes
condiciones maternas.El Dr. Jansson demostró que la activación de mTOR placentaria conduce al sobrecrecimiento fetal, la inhibición de mTOR da como resultado la restricción del crecimiento fetal y la homeostasis de mTOR está relacionada con el peso óptimo al nacer. Estos hallazgos son de vital
More news about: March of Dimes
Jan 08, 2026, 09:00 ET Kazia Therapeutics to Participate in J.P. Morgan Healthcare Conference Week; Clinical and Translational Update Anticipated Before Month-End
anticipated triple negative breast cancer clinical and biomarker update before the end of the month. At the same time, renewed industry focus on the PI3K/mTOR pathway—particularly in hormone receptor–positive, HER2-negative breast cancer—underscores the growing relevance of approaches that are designed to
More news about: Kazia Therapeutics Limited
Jan 07, 2026, 10:32 ET How $594B in Precision Tech is Cracking the Metastatic Cancer Code
presented new data at the 2025 San Antonio Breast Cancer Symposium demonstrating that paxalisib, its brain-penetrant dual PI3K/mTOR inhibitor, disrupted highly aggressive circulating tumor cell clusters and reinvigorated exhausted immune populations across both HER2-positive and
More news about: USA News Group
Jan 06, 2026, 03:19 ET Clarivate Identifies Eleven Potential Blockbuster and Transformative Therapies in its 2026 Drugs to Watch Report
Gedatolisib developed by Celcuity | Breast cancerA pan-PI3K/mTOR inhibitor, administered intravenously once weekly for three weeks in a 28-day cycle to treat HR-positive/HER2-negative metastatic breast cancer, also
More news about: Clarivate Plc
Jan 06, 2026, 03:07 ET Clarivate Identifies Eleven Potential Blockbuster and Transformative Therapies in its 2026 Drugs to Watch Report
Gedatolisib developed by Celcuity | Breast cancerA pan-PI3K/mTOR inhibitor, administered intravenously once weekly for three weeks in a 28-day cycle to treat HR-positive/HER2-negative metastatic breast cancer, also
More news about: Clarivate Plc
Dec 22, 2025, 08:00 ET Kazia Therapeutics Regains Full Nasdaq Listing Compliance
(NASDAQ: KZIA) is an innovative oncology-focused drug development company, based in Sydney, Australia. Our lead program is paxalisib, a brain-penetrant pan-PI3K/mTOR inhibitor, which is being developed to treat multiple forms of brain cancer, including glioblastoma and brain metastases. A Phase 1b clinical trial
More news about: Kazia Therapeutics Limited
Dec 18, 2025, 21:59 ET Kanazawa University research: a new strategy for immune tolerance
vivo Treg induction enhanced by mTOR inhibition In animal models, AP-EVs selectively activated antigen-specific CD4⁺ T cells based on their pMHCII specificity. However, Foxp3 induction required the co-administration of rapamycin, an mTOR inhibitor known to promote Treg
More news about: Kanazawa University
Dec 16, 2025, 09:00 ET Fatty15 Lands Best Longevity Supplement Brand of 2025
inhibiting mTOR, as well as targets key hallmarks of aging by
More news about: Seraphina Therapeutics
Dec 10, 2025, 08:00 ET Kazia Therapeutics Highlights New Clinical and Translational Findings Demonstrating Paxalisib's Ability to Reinvigorate Anti-Tumor Immunity Across Multiple Advanced Breast Cancer Populations including TNBC and HER2+
Symposium (SABCS) providing compelling mechanistic and early clinical evidence supporting the activity of paxalisib, the Company's brain-penetrant dual PI3K/mTOR inhibitor, across both HER2-positive metastatic breast cancer and triple-negative breast cancer (TNBC). The results, originating from advanced
More news about: Kazia Therapeutics Limited
Dec 02, 2025, 09:00 ET Kazia Therapeutics Announces Pricing of $50.0 Million Private Placement of Equity Securities
cash equivalents and marketable securities, to support the continued clinical development of its lead program paxalisib, a brain-penetrant dual PI3K/mTOR inhibitor currently in clinical trials for both brain cancer and advanced breast cancer, advancing the PD-L1 degrader program, and for general corporate
More news about: Kazia Therapeutics Limited
Nov 18, 2025, 16:15 ET Kazia Therapeutics Achieves Initial iCR (Immune-Complete Response) in Metastatic TNBC and Delivers Q4 Business Update with Breakthroughs Across Breast Cancer, Immuno-Oncology, and GBM Regulatory Strategy
diagnostics. December 10, 2025 — PS2-10-02 "Liquid Biopsy Tracking of PI3K-mTOR Residual Disease Signatures in Metastatic Breast Cancer", Presenter: Prof. Sudha Rao, QIMR Berghofer (Australia) December
More news about: Kazia Therapeutics Limited
Nov 17, 2025, 09:07 ET Atossa Highlights Emerging Opportunity for (Z)-Endoxifen in Duchenne Muscular Dystrophy, Including Symptomatic Female Carriers, Following Peer-Reviewed Publication and Scientific Presentation
The paper emphasizes (Z)-endoxifen's direct estrogen-receptor (ER) modulation, allosteric inhibition of PKC (notably PKC-β1), and effects along AKT/mTOR and NF-κB axes, mechanisms that together may help slow disease progression when used as an adjunct to standard care. Notably, the authors underscore
More news about: Atossa Therapeutics Inc
Oct 30, 2025, 06:43 ET Breckenridge announces launch of Everolimus Tablets, 1mg, generic version of Zortress®
Everolimus is an mTOR inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in adult patients in kidney and liver transplantation. The product will
More news about: Breckenridge Pharmaceutical, Inc.
Oct 29, 2025, 08:30 ET Nanomedicine Innovations Transforming Oncology Drug Delivery and Bioavailability
uneven distribution within the body, forcing higher dosages and exposing patients to unnecessary toxicity. This challenge is especially evident with mTOR inhibitors, kinase inhibitors and vascular-disrupting agents, where dose-limiting toxicity can halt development despite strong preclinical results.
More news about: NetworkNewsWire
Oct 27, 2025, 08:30 ET Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology
solubility, steep metabolism and imprecise biodistribution, forcing high doses and resulting in systemic toxicity. This is especially problematic in mTOR inhibitors, kinase inhibitors, and vascular-disrupting agents, where dose-limiting toxicity can halt development even when preclinical data were strong.
More news about: NetworkNewsWire
Oct 27, 2025, 07:15 ET Kazia Therapeutics to Request FDA Type C Meeting to Discuss Overall Survival Data in GBM and Potential NDA Filing in Alignment with FDA initiative Project FrontRunner
drug development company, based in Sydney, Australia. Our lead program is paxalisib, an investigational brain penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of cancer. Licensed from Genentech in late 2016, paxalisib is or has been the subject of ten
More news about: Kazia Therapeutics Limited
Oct 07, 2025, 08:30 ET Kazia Therapeutics Announces Collaboration and In-Licensing Agreement for First-in-Class PD-L1 Protein Degrader Program
15 months. Kazia also intends to explore synergistic opportunities to combine NDL2 with its existing pipeline assets, including paxalisib (a pan-PI3K/mTOR inhibitor) and EVT801 (a selective VEGFR3 inhibitor), given their complementary mechanisms of action in modulating the tumor microenvironment.
More news about: Kazia Therapeutics Limited